Rituxan Could Be Top Source Of Price Inflation Rebates In Medicare Part B

07 Sep 2017

HHS Office of Inspector General estimates $1.4bn to $1.8bn could have been saved in Medicare Part B in 2015 if manufacturers provided rebates when drug prices increased faster than inflation.

Inflation-based rebates for Genentech Inc.'s Rituxan (rituximab) could generate at least $269m in savings for the Medicare Part B program, according to an analysis by the HHS Office of Inspector General released Sept. 5.

Rituxan could be the leading source of inflation-based rebates, based on expenditures on the drug and its history of price...